Immunomodulator Class
Adalimumab
Brand: Humira / Exemptia / Hyrimoz
Subclass: TNF-alpha inhibitor (human mAb)
PK:
t½ 14 days | Clearance: reticuloendothelial
severe
AE: Injection-site reactions, serious infections (TB, fungal), malignancy risk (lymphoma), hepatitis B reactivation, cytopenias
AE: Injection-site reactions, serious infections (TB, fungal), malignancy risk (lymphoma), hepatitis B reactivation, cytopenias
Certolizumab Pegol
Brand: Cimzia
Subclass: PEGylated anti–TNF-α antibody fragment (Fab’)
PK:
t½ 14 days | Clearance: reticuloendothelial
severe
AE: Infections (TB, invasive fungal), injection reactions, hepatotoxicity, cytopenias, malignancy risk
AE: Infections (TB, invasive fungal), injection reactions, hepatotoxicity, cytopenias, malignancy risk
Etanercept
Brand: Enbrel / Intacept
Subclass: TNF-alpha inhibitor (receptor-Fc fusion protein)
PK:
t½ 4 days | Clearance: reticuloendothelial
severe
AE: Injection-site reactions, serious infections (TB, fungal), reactivation of HBV, demyelinating disease, neutropenia
AE: Injection-site reactions, serious infections (TB, fungal), reactivation of HBV, demyelinating disease, neutropenia
Golimumab
Brand: Simponi / Golimumax
Subclass: TNF-alpha monoclonal antibody (IgG1κ)
PK:
t½ 14 days | Clearance: reticuloendothelial
severe
AE: Serious infections (TB, fungal), injection reactions, hepatotoxicity, demyelinating disease, CHF exacerbation
AE: Serious infections (TB, fungal), injection reactions, hepatotoxicity, demyelinating disease, CHF exacerbation
Guselkumab
Brand: Tremfya
Subclass: IL-23 (p19) monoclonal antibody
PK:
t½ 16 days | Clearance: reticuloendothelial
moderate
AE: URTIs, headache, injection site reactions, arthralgia, diarrhea
AE: URTIs, headache, injection site reactions, arthralgia, diarrhea
Infliximab
Brand: Remicade / Inflectra
Subclass: TNF-alpha inhibitor (chimeric mAb)
PK:
t½ 9.5 days | Clearance: reticuloendothelial
severe
AE: Infusion reactions, severe infections (TB, fungal), hepatotoxicity, reactivation of hepatitis B, demyelination, heart failure exacerbation
AE: Infusion reactions, severe infections (TB, fungal), hepatotoxicity, reactivation of hepatitis B, demyelination, heart failure exacerbation
Ixekizumab
Brand: Taltz
Subclass: IL-17A monoclonal antibody
PK:
t½ 13 days | Clearance: reticuloendothelial
moderate
AE: Injection site reactions, infections (URTI, candidiasis), neutropenia, inflammatory bowel disease flare
AE: Injection site reactions, infections (URTI, candidiasis), neutropenia, inflammatory bowel disease flare
Risankizumab
Brand: Skyrizi
Subclass: IL-23 (p19) monoclonal antibody
PK:
t½ 28 days | Clearance: reticuloendothelial
moderate
AE: URTI, headache, injection site reactions, fatigue
AE: URTI, headache, injection site reactions, fatigue
Secukinumab
Brand: Cosentyx
Subclass: IL-17A monoclonal antibody
PK:
t½ 27 days | Clearance: reticuloendothelial
moderate
AE: Infections (URTI common), Candida infections, neutropenia, inflammatory bowel disease flare
AE: Infections (URTI common), Candida infections, neutropenia, inflammatory bowel disease flare
Ustekinumab
Brand: Stelara
Subclass: IL-12/IL-23 monoclonal antibody
PK:
t½ 21 days | Clearance: reticuloendothelial
moderate
AE: Infections (URTI), injection-site reactions, malignancy risk (rare), reversible posterior leukoencephalopathy syndrome (very rare)
AE: Infections (URTI), injection-site reactions, malignancy risk (rare), reversible posterior leukoencephalopathy syndrome (very rare)